This article has been corrected: The authors requested the replacement of Figure 4E and Table 1. Figure 4E (ciRs-6+miR-nc) was quite similar to Supplementary Figure 1D (si-3 in T24 cells) and was slightly updated. Changes of Table 1 are done to correct the statistical mistakes.

These corrections do not change the content of the publication and do not affect the conclusion of this research. The authors apologize for the unintentional mistakes.

The corrected Figure and Table are provided below.

miR-653 rescues the tumor suppressive effect of ciRs-6 in bladder cancer. (E) Clone formation assays were used to evaluate clone forming ability.

Figure 4. miR-653 rescues the tumor suppressive effect of ciRs-6 in bladder cancer. (E) Clone formation assays were used to evaluate clone forming ability.

Table 1. Relationship between ciRs-6 level and clinical characteristics in bladder cancer.

TotalPatientsExpression of ciRs-6
HighLowp
Age(mean)5047.93152.0690.395
Gender
Male4522230.753
Female1376
Tumor stage
Tis/Ta/T131229<0.001
T217710
T3/T410010
Grade
High205150.006
Low382414
Number of tumors
Solitary4123180.149
Multiple17611
Lymph node metastasis
Negative2313100.421
Positive351619
Follow-up (month, mean)33.2333.0033.450.047